Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase in posterior circulation stroke (TRUST)
NCT07073469Phase 3Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
Phase 3, randomised, open-label trial of tenecteplase in ischemic stroke (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Modified Rankin Scale at 90 days. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07073469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07073469.